Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from CardieX ( (AU:CDX) ).
Cardiex Limited has received approval from the Therapeutic Goods Administration (TGA) for its CONNEQT Pulse arterial health monitor, allowing it to be marketed in Australia. This device, which has already been cleared by the U.S. FDA, is designed for both clinical and remote patient monitoring, capturing key arterial health biomarkers. With this approval, Cardiex plans to explore commercialization opportunities in Australia, initially targeting pharmaceutical, research, and clinician markets. This milestone reflects Cardiex’s commitment to expanding its regulatory and commercial reach, with a continued primary focus on the U.S. market while laying the groundwork for growth in Australia.
More about CardieX
Cardiex is a company focused on advancing medical technology for vascular health, offering products such as medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders. Their products are based on their market-leading SphygmoCor® vascular biomarker technology. Cardiex is listed on the Australian Stock Exchange (ASX:CDX).
Average Trading Volume: 244,356
Technical Sentiment Signal: Sell
Current Market Cap: A$17.05M
See more data about CDX stock on TipRanks’ Stock Analysis page.